Plūme Pāvils, Losevs Igors, Loseva Elizabete Anna, Maļcevs Aleksandrs, Suhorukovs Vadims, Jegorova Olga, Ševeļovs Viktors, Jušinskis Jānis
Latvian Transplant Center, Pauls Stradiņš Clinical University Hospital, LV-1002 Riga, Latvia.
Department of Surgery, Riga Stradiņš University, LV-1007 Riga, Latvia.
Medicina (Kaunas). 2025 Sep 10;61(9):1641. doi: 10.3390/medicina61091641.
: Kidney transplantation remains the gold-standard treatment for end-stage renal disease (ESRD). For deceased donor transplantation, optimal allograft preservation represents a critical determinant of success. While static cold storage (SCS) has been the historical standard, hypothermic machine perfusion (HMP) has emerged in recent decades as a technologically advanced alternative. However, comparative data from smaller-volume centers utilizing exclusively donation after brain death (DBD) donors remain scarce. Materials and Methods: This retrospective single-center study included 94 patients who received kidney transplants from deceased DBD donors between January 2018 and December 2024. We employed a paired kidney study design where one kidney from each donor was preserved using HMP (LifePort, set at 30/20 mm Hg pressure), while the contralateral kidney was stored in SCS. Parameters compared were creatinine concentration in recipient serum after transplantation, DGF, acute rejection and hospital stay. : The HMP group had a significantly longer cold ischemia time (CIT) (18.09 ± 5.91 h, range: 6.5-34.0 h) compared to the SCS group (12.36 ± 5.18 h, range: 4.0-23.0 h; < 0.005). The DGF rate was significantly lower in the HMP group (4.3%) than the SCS group (25.5%) ( = 0.004). HMP was also associated with a shorter mean hospitalization (11.81 vs. 15.66 days, = 0.008) and superior early graft function, particularly in kidneys with CIT ≥ 18 h, which showed significantly lower serum creatinine at day 14 (124.48 vs. 164.89 µmol/L, = 0.036). : HMP usage in kidney transplantation decreased the possibility for DGF in DBD donors and shortened the post-op hospitalization time. It is a feasible method for kidney storage before transplantation even in a case of prolonged CIT.
肾移植仍然是终末期肾病(ESRD)的金标准治疗方法。对于尸体供肾移植,最佳的同种异体肾保存是成功的关键决定因素。虽然静态冷保存(SCS)一直是历史标准,但低温机器灌注(HMP)在近几十年中已成为一种技术先进的替代方法。然而,来自仅使用脑死亡后捐赠(DBD)供体的小容量中心的比较数据仍然稀缺。材料和方法:这项回顾性单中心研究纳入了94例在2018年1月至2024年12月期间接受来自已故DBD供体肾移植的患者。我们采用配对肾研究设计,每个供体的一个肾使用HMP(LifePort,设置在30/20 mmHg压力)保存,而对侧肾保存在SCS中。比较的参数包括移植后受者血清中的肌酐浓度、延迟性移植肾功能恢复(DGF)、急性排斥反应和住院时间。:与SCS组(12.36±5.18小时,范围:4.0 - 23.0小时;P<0.005)相比,HMP组的冷缺血时间(CIT)明显更长(18.09±5.91小时,范围:6.5 - 34.0小时)。HMP组的DGF发生率(4.3%)明显低于SCS组(25.5%)(P = 0.004)。HMP还与较短的平均住院时间相关(11.81天对15.66天,P = 0.008)以及更好的早期移植肾功能,特别是在CIT≥18小时的肾脏中,在第14天血清肌酐明显更低(124.48对164.89 μmol/L,P = 0.036)。:肾移植中使用HMP降低了DBD供体发生DGF的可能性,并缩短了术后住院时间。即使在CIT延长的情况下,它也是移植前肾脏保存的一种可行方法。